Neoadjuvant Chemotherapy (UFT· CDDP Therapy) for Borrmann 4 Type Gastric Carcinoma

1993 ◽  
pp. 369-371
Author(s):  
Nobuhiko Tadaoka ◽  
Sumio Takayama ◽  
Chiaki Sekine ◽  
Tsutomu Fujimori ◽  
Hiroshi Nimura ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Gastric Carcinoma

scholarly journals Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma

BMC Surgery ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Catharina Ruf ◽  
Oliver Thomusch ◽  
Matthias Goos ◽  
Frank Makowiec ◽  
Gerald Illerhaus ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Gastric Carcinoma ◽  
Advanced Gastric Carcinoma

Neoadjuvant chemotherapy (NCT) in locally advanced gastric carcinoma (LAGC)

1993 ◽  
Vol 29 ◽  
pp. S107
Author(s):  
Ph Lasser ◽  
Ph Rougier ◽  
M Ducreux ◽  
M Mahjoubi ◽  
D Elias ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Gastric Carcinoma ◽  
Locally Advanced ◽  
Advanced Gastric Carcinoma

P70. Incidence of thromboembolism during neoadjuvant chemotherapy for oesophago-gastric carcinoma

2012 ◽  
Vol 38 (11) ◽  
pp. 1124-1125 ◽  
Author(s):  
Siobhan Muthiah ◽  
Helen Jaretzke ◽  
Michael Griffin ◽  
Shajahan Wahed ◽  
Kate Sumpter
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Gastric Carcinoma

scholarly journals Clinical Effectiveness of Neoadjuvant Chemotherapy in Gastric Carcinoma and Exploration of Perioperative Imaging Assessment Parameters

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Jiajun Lai ◽  
Junsheng Li ◽  
Xianwei Mo
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Gastric Carcinoma ◽  
Tumor Regression ◽  
Clinical Effectiveness ◽  
Clinical Staging ◽  
Tumor Regression Grade ◽  
Clinical Value ◽  
Advanced Gastric Carcinoma ◽  
Before And After ◽  
Assessment Approach

Background and Aims. Due to the difficulty in clinical staging, a simple and feasible perioperative assessment approach for guiding personalized neoadjuvant chemotherapy (NAC) is lacking. We investigated the clinical value of NAC in advanced gastric carcinoma (GC) and the concordance between perioperative imaging and postoperative pathological assessments. Methods. This study included 62 patients with advanced GC who received NAC between January 2012 and December 2018. The preoperative and postoperative T stages, postoperative pathological tumor regression grade (TRG), and changes in computed tomography (CT) values after NAC were assessed. Follow-ups were conducted to obtain the median survival time (MST), and Kaplan–Meier survival curves were plotted. Results. The T stages significantly differed between before and after NAC ( p = 0.001 ). The MST of patients in the TRG0 group was significantly different from that of patients in the TRG1+2 and TRG3 groups ( p = 0.223 ). The percentages of positive lymph nodes were 0%, 24.17%, and 27.64% in the TRG0, TRG1+2, and TRG3 groups, respectively. TRG was correlated with changes in CT values before and after NAC, and the extent of change was associated with patient prognosis. Conclusions. Perioperative imaging can be used to assess the short-term effectiveness of NAC for patients with GC.

S-1 plus oxaliplatin compared with fluorouracil/leucovorin/oxaliplatin as neoadjuvant chemotherapy for locally advanced gastric carcinoma.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 147-147
Author(s):  
Jiren Yu ◽  
Yijun Wu ◽  
Yuan Gao ◽  
Qianyun Shen ◽  
Qing Zhang ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Gastric Carcinoma ◽  
Clinical Response ◽  
Response Rate ◽  
Locally Advanced ◽  
Preoperative Staging ◽  
Complete Response ◽  
Clinical Response Rate ◽  
R0 Resection ◽  
Advanced Gastric Carcinoma

147 Background: Perioperative chemotherapy could improve the prognosis compared with surgery alone. This study is to compare the efficacy and safety of S-1 and oxaliplatin (SOX) with fluorouracil, leucovorin and oxaliplatin (FOLFOX) as neoadjuvant chemotherapy for locally advanced gastric carcinoma. Methods: Patients with histologically confirmed locally advanced gastric carcinoma were enrolled and divided into two groups. Preoperative staging and response evaluation was achieved mainly by gastroscopy and abdominal computer tomography. Neoajuvant chemotherapy consisted of 2-6 cycles of S-1 80mg/m2 (2-week administration and 1-week rest) plus oxaliplatin 130mg/m2 on Day1 in SOX group, or 2 h infusion of 130mg/m2 oxaliplatin plus 2h infusion of 400 mg/m2 leucovorin, followed by infusion of 400 mg/m2 5-fluorouracil on Day 1 and 46 h 2.4 g/m2 bolus in FOLFOX group. The clinical response was evaluated after 2 cycles of chemotherapy, and surgery was attempted. Results: From 2009.9 to 2011.5, 88 patients were enrolled in this study(56 in SOX and 32 in FOLFOX). The clinical response rate was significant higher in the SOX compared with FOLFOX (54.7% vs. 31.2%, p=0.03). 68 patients received surgery(45 in SOX and 23 in FOLFOX), R0 resection rate was similar in both group (SOX: 93.3% vs. FOLFOX: 82.6%, p=0.22). Pathological complete response was observed in 3 patients in SOX group. All enrolled patients were evaluated for the adverse events (AE). The most common non-hematological AE was nausea (57.1% in SOX and 50% in FOLFOX) and vomiting (41.1% in SOX and 40.6% in FOLFOX). The major hematological AE included thrombocytopenia (37.5% in SOX and 21.9% in FOLFOX), neutropenia (33.9% in SOX and 53.1% in FOLFOX) and leukocytopenia (32.1% in SOX and 40.6% in FOLFOX). Conclusions: SOX had higher response rate and acceptable toxicity compared with FOLFOX as neoadjuvant chemotherapy.

Preoperative (“Neoadjuvant”) Chemotherapy in Locally Advanced Gastric Carcinoma

1989 ◽  
pp. 161-168 ◽  
Author(s):  
H. Wilke ◽  
P. Preusser ◽  
U. Fink ◽  
W. Achterrath ◽  
H.-J. Meyer ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Gastric Carcinoma ◽  
Locally Advanced ◽  
Advanced Gastric Carcinoma
Sign in / Sign up

Export Citation Format

Share Document